Clinical Study on the Efficacy and Safety of rTMS Regulating Slow-wave Sleep to Delay the Progression of Parkinson's Disease
At present, no drug therapy has been proven to delay the progression of Parkinson's disease (PD). rTMS, as a non-invasive neuromodulation method, can regulate Slow-wave sleep (SWS). SWS is recognized closely related to neurodegeneration. However, there has been no clinical studies on if rTMS could delay the progression of PD by regulating SWS. The main purpose of this study is to explore the changes of SWS in non-rapid eye movement (NREM) sleep period in PD patients by using rTMS, and the relationship with potential improvements of SWS and motor symptom delay. The study aims to find a potential new treatment strategy to delay the neurodegenerative process in PD patients by modulating SWS by rTMS.
• Meet the clinically definite or clinically probable PD according to the MDS 2015 version.
• Chinese Han population (three generations), age greater than or equal to 50 years old, less than or equal to 80 years old, male or female.
• Hoehn-Yahr stages 1-4.
• The dose of levodopa drug therapy was stable three weeks before enrollment and during the follow-up period.
• Right-handed.
• The patient signed a written informed consent.